BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1940615)

  • 1. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases.
    Brenner BG; Gryllis C; Wainberg MA
    J Leukoc Biol; 1991 Dec; 50(6):628-40. PubMed ID: 1940615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.
    Tyler DS; Stanley SD; Nastala CA; Austin AA; Bartlett JA; Stine KC; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1990 May; 144(9):3375-84. PubMed ID: 2329275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.
    Gryllis C; Wainberg MA; Gornitsky M; Brenner B
    AIDS; 1990 Dec; 4(12):1205-12. PubMed ID: 2088399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
    Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
    J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.
    Brenner BG; Gryllis C; Gornitsky M; Cupples W; Wainberg M
    Anticancer Res; 1991; 11(2):969-74. PubMed ID: 2064353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
    Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in natural immunity during the course of HIV-1 infection.
    Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
    Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals.
    Stine KC; Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
    Cell Immunol; 1991 Aug; 136(1):165-72. PubMed ID: 1905587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective natural immunity: an early manifestation of human immunodeficiency virus infection.
    Ullum H; Gøtzsche PC; Victor J; Dickmeiss E; Skinhøj P; Pedersen BK
    J Exp Med; 1995 Sep; 182(3):789-99. PubMed ID: 7650485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity.
    Brenner BG; Vo C; Wainberg MA
    Leukemia; 1994 Apr; 8 Suppl 1():S183-5. PubMed ID: 8152288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals.
    Gryllis C; Wainberg MA; Bentwich Z; Gornitsky M; Brenner BG
    Clin Exp Immunol; 1992 Sep; 89(3):356-61. PubMed ID: 1381298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells.
    Mason LH; Mathieson BJ; Ortaldo JR
    J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing high-throughput methods to measure NK cell-mediated antibody dependent cellular cytotoxicity during HIV-infection.
    Konstantinus IN; Gamieldien H; Mkhize NN; Kriek JM; Passmore JA
    J Immunol Methods; 2016 Jul; 434():46-52. PubMed ID: 27094485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.
    Brenner BG; Gornitsky M; Wainberg MA
    Clin Diagn Lab Immunol; 1994 Sep; 1(5):538-44. PubMed ID: 8556498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.
    Lin SJ; Roberts RL; Ank BJ; Nguyen QH; Thomas EK; Stiehm ER
    J Clin Immunol; 1998 Sep; 18(5):335-45. PubMed ID: 9793826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
    Katz JD; Mitsuyasu R; Gottlieb MS; Lebow LT; Bonavida B
    J Immunol; 1987 Jul; 139(1):55-60. PubMed ID: 3584988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
    García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
    Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.
    Baum LL; Cassutt KJ; Knigge K; Khattri R; Margolick J; Rinaldo C; Kleeberger CA; Nishanian P; Henrard DR; Phair J
    J Immunol; 1996 Sep; 157(5):2168-73. PubMed ID: 8757343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.